Staidson (Beijing) BioPharmaceuticals Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CNY 65.02 million compared to CNY 123.34 million a year ago. Revenue was CNY 65.02 million compared to CNY 123.34 million a year ago.

Net loss was CNY 48.73 million compared to CNY 24.41 million a year ago. Basic loss per share from continuing operations was CNY 0.1 compared to CNY 0.05 a year ago. Diluted loss per share from continuing operations was CNY 0.1 compared to CNY 0.05 a year ago.